We are live on ! Find out more
VMI

VHCP Management III Portfolio holdings

AUM $504M
1-Year Est. Return 683.12%
This Fund
S&P 500
This Quarter Est. Return
-10.57%
1 Year Est. Return
+683.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$138M
AUM Growth
+$5.23M
Cap. Flow
+$33.5M
Cap. Flow %
24.35%
Top 10 Hldgs %
93.9%
Holding
18
New
5
Increased
1
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$15.5M
2
DBVT
DBV Technologies
DBVT
+$10.3M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$9.34M
4
KA
Kineta, Inc. Common Stock
KA
+$4.11M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$3.36M

Top Sells

Rank Stock Value
1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$10.7M
2
APLS
Apellis Pharmaceuticals
APLS
+$894K
3
CCXI
ChemoCentryx, Inc.
CCXI
+$493K

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
1
DELISTED
KalVista Pharmaceuticals
KALV
$25.4M 18.45%
1,284,931
– –
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$2.28B
$24.7M 17.96%
3,061,091
– –
ORTX
3
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$16.4M 11.91%
+104,152
New +$15.5M
TCDA
4
DELISTED
Tricida, Inc. Common Stock
TCDA
$15.3M 11.15%
650,585
– –
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$14.7M 10.67%
1,159,789
– –
RARX
6
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$10.8M 7.87%
+594,713
New +$9.34M
KNSA icon
7
Kiniksa Pharmaceuticals
KNSA
$5.8B
$9.21M 6.69%
327,777
– –
KDMN
8
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.97M 3.61%
2,388,572
– –
DBVT
9
DBV Technologies
DBVT
$799M
$4.09M 2.97%
+63,680
New +$10.3M
MRNS
10
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.61M 2.63%
314,741
+146,673
+87% +$2.97M
PTGX icon
11
Protagonist Therapeutics
PTGX
$8.79B
$2.85M 2.07%
+423,176
New +$3.36M
KA
12
DELISTED
Kineta, Inc. Common Stock
KA
$2.75M 2%
+6,062
New +$4.11M
BLPH
13
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$1.82M 1.33%
151,625
– –
MTVA
14
MetaVia Inc
MTVA
$7.33M
$704K 0.51%
13
– –
CNST
15
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$267K 0.19%
66,667
– –
APLS
16
DELISTED
Apellis Pharmaceuticals
APLS
– –
-50,290
Closed -$894K
CCXI
17
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-39,036
Closed -$493K
ECYT
18
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-600,000
Closed -$10.7M

Similar funds

BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return

VHCP Management III's Q4 2018 Portfolio in Review

As of Q4 2018, VHCP Management III held 18 positions worth $138M, up 4% from $132M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

VHCP Management III deployed $33.5M of net new capital in Q4 2018, opening 5 new positions and adding to 1 existing holding. Its largest new stake was Orchard Therapeutics plc American Depositary Shares: 104,152 shares worth $16.4M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

On the sell side, the most notable exit was Endocyte, Inc. Common Stock, an estimated $10.7M sold.

  • VHCP Management III's largest Q4 2018 buy was Orchard Therapeutics plc American Depositary Shares: 104,152 shares worth $16.4M.
  • VHCP Management III added most to Marinus Pharmaceuticals, Inc in Q4 2018, an estimated $2.97M increase.
  • VHCP Management III fully exited Endocyte, Inc. Common Stock in Q4 2018, selling an estimated $10.7M.
  • VHCP Management III's ten largest holdings make up 94% of its $138M portfolio in Q4 2018.
  • VHCP Management III opened 5 new positions and closed 3 in Q4 2018.
  • VHCP Management III's portfolio value rose 4% quarter-over-quarter to $138M.

Based on VHCP Management III's 13F filing for Q4 2018, filed 13 Feb 2019.